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Vikram Paruchuri, MD, and Richard P. Cambria, MD, Boston, Mass
Objective:Endovascular therapy for chronic mesenteric ischemia (CMI) has been increasingly utilized. Early outcomes compare
favorably with open mesenteric bypass—the current gold standard. The goal of this study is documentation of intermediate-
term anatomic and functional outcomes of endovascular mesenteric revascularization for symptomatic CMI.
Methods: This is a retrospective review of all patients undergoing endovascular treatment of symptomatic CMI from July
2002 to March 2008. Study endpoints included periprocedural mortality, major morbidity, patency, symptomatic
recurrence, and survival. Endpoints were analyzed using actuarial methods.
Results: Sixty-six mesenteric arteries (78.8% stenotic/21.2% occluded) were treated in 49 patients. One or more vessels were
treated in each case; however, four mesenteric artery total occlusions (3 SMAs/1 IMA) could not be crossed. Initial symptom
relief was noted in 89.8% (n44) with no change in 5 patients. Single-vessel treatments were performed in 32 patients (65.3%)
and two-vessel interventions in 17 (34.7%). The 30-day mortality rate was 2.0% (n  1). Major complications occurred in 8
patients (16.3%). The mean follow-up duration was 37.4  2.98 months (range, 0-66). Restenosis on follow-up imaging
occurred in 64.9% (n  24) of the 37 patients who had radiographic surveillance at a mean follow-up interval of 8.5  1.9
months and was diagnosed most often by Duplex scan or computed tomographic angiography (CTA). Fourteen patients
(28.6%) developed recurrent symptoms with 13 requiring a reintervention. Actuarial 36-month freedom from symptomatic
recurrence was 60.9% 9.4%. Two-vessel treatment was protective against symptom recurrence (P .0014) and reinterven-
tion (P  .0060) by univariate analysis. A total of 19 reinterventions were required in 14 patients (28.6%) at a mean of 17
months from the original treatment. Primary patency at 36 months was 63.9  8.5%. Actuarial survival at 48 months was
81.1%  6.1% with no CMI-related deaths in the study cohort.
Conclusion: Intermediate (3-year) follow-up indicates that significant restenosis and symptom recurrence are common
following the endovascular treatment of symptomatic CMI. Thirty percent of the cohort required a reintervention,
one-third of which were conversions to surgical reconstruction. Similar to the surgical paradigm of two-vessel
revascularization, endovascular treatment of multiple mesenteric arteries produced better outcomes. A first-line endo-
vascular approach to patients with CMI is a reasonable clinical strategy, but close follow-up is mandatory. (J Vasc Surg
2010;51:140-7.)Atherosclerotic disease of the mesenteric arteries is
estimated to affect 17% of patients over age 65.1 Although
many patients remain asymptomatic, those with stenosis or
occlusion of two or more mesenteric arteries can develop
chronic mesenteric ischemia (CMI) and/or progression to
catastrophic intestinal infarction. Symptomatic CMI is also
a predictor of future acute events. Recent studies have
shown that 40% to 50% of patients presenting with acute
mesenteric ischemia (AMI) had prior symptoms of CMI.2,3
To wit, CMI remains a highly morbid disease with the dual
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140goals of therapy being symptom relief and preventing fu-
ture acute ischemic events. In the endovascular era, the best
approach to achieve these goals remains controversial.4-7
The first successful operative intervention for CMI was
performed at the Massachusetts General Hospital and re-
ported by Shaw and Maynard in 1958.8 Open mesenteric
bypass (OR) remains the gold standard for patients with
symptomatic CMI because of its exceptional long-term
durability.2,3 However, the morbidity (5%-30%) and mor-
tality (2%-12%) ranges associated with OR are not trivial,
related to both comorbid risk factors and nutritional deple-
tion, common in this population.2-4,9-13
Endovascular therapy, consisting of percutaneous
transluminal angioplasty and stenting (PTA/stent), has
been increasingly used to treat CMI, in part, due to its
success in other vascular beds. Since the first reports of
percutaneous treatment of visceral vessels,14 operator skills
and technology have improved; now both mesenteric oc-
clusions and stenoses can be successfully treated.15 Several
small single-center series report positive early safety and
efficacy.16-22 Early morbidity (0%-18%) and mortality (0%-
10%) rates compare favorably with OR, however, the im-
pact of an endovascular-first treatment strategy on long-
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Prior endovascular CMI studies have reported a significant
incidence of anatomic failure with 2-year stent patency
ranging from 30% to 90%.4-6,15,24,25 Indeed, early experi-
ence from our institution yielded a modest 58% 1-year
primary patency after mesenteric PTA/stent.4 Follow-up
of symptomatic recurrence after endovascular therapy has
been short, and the question remains whether the positive
impact of low periprocedural morbidity and mortality on
survival is sustainable despite disease recurrence. In addition,
the exact nature and consequence of recurrence is unk-
nown. The goal of this study is to document the intermediate-
term (3-year) anatomic and functional outcomes of endo-
vascular mesenteric revascularization in a population with
symptomatic CMI.
METHODS
This is a retrospective record review of all patients (n
49) who underwent endovascular treatment of symptom-
atic CMI at the Massachusetts General Hospital from July
2002 to March 2008. Over the same period, 18 primary
open-surgical bypass procedures were performed for CMI,
with the majority occurring prior to 2005. A total of 57% of
this study population was included in a prior report4 that
focused on the feasibility of endovascular therapy for CMI
and short-term outcomes; the current study focuses on
longer-term outcomes and anatomic durability of endovas-
cular therapy. For a diagnosis of CMI, at least one symptom
was required: postprandial abdominal pain, significant
weight loss, food fear, nausea, vomiting, or diarrhea along
with angiographic evidence of a hemodynamically signifi-
cant stenosis (70%) of1mesenteric artery. Patients with
AMI or treated with primary OR were excluded. Patient
demographics, clinical presentation, diagnostic and radio-
graphic results, nutritional status, procedure details, and
long-term follow-up data were collected. Cardiac disease
was defined as any history of myocardial infarction, angina,
congestive heart failure, or coronary intervention, includ-
ing percutaneous transluminal coronary angioplasty or cor-
onary artery bypass grafting. Renal disease was defined as a
baseline serum creatinine level of 1.5 g/dL. Peripheral
vascular disease was characterized as claudication or lower
extremity intervention for ischemia. Weight loss was de-
fined as an unintentional drop of 5 pounds. Diabetes
mellitus as an associated diagnosis included patients with
any history of the disease, regardless of current treatment
regimen. The Institutional Review Board of the Harvard
Medical School and the Massachusetts General Hospital
approved the experimental protocol.
Follow-up. Patient records, clinical office visits, and
radiographic imaging were reviewed. Although no uniform
follow-up protocol was followed, patients were generally
seen 6 weeks after discharge for symptom assessment and
establishment of a radiologic baseline for surveillance. Pa-
tients were then seen at 6- to 12-month intervals depend-
ing on the results of these initial studies. The imaging
study most often obtained was a Duplex ultrasound scan
(n  19; 51.4%) followed by a computed tomographicangiogram (CTA) (n 13; 35.0%). Patients were evaluated
and/or studied with increased frequency if symptoms re-
curred.
Study endpoints:
● Periprocedural morbidity and mortality were defined
as adverse events occurring within 30 days of the
procedure or during the initial hospitalization. Major
morbidity included any occurrence resulting in a pro-
longation of the hospital stay: bowel infarction, myo-
cardial infarction, stroke, acute renal failure, respira-
tory failure, or multisystem organ failure. Vascular
access site complications that required operative repair
were also documented and reported.
● Primary patency was considered failed when patients
developed in-stent restenosis/occlusion associated
with the return of clinical symptoms. Elevated duplex
scan velocities alone were not considered a failure of
primary patency. In the absence of symptoms, these
patients underwent continued surveillance. If duplex
scan velocities remained elevated, an angiogram was
often performed. In all of these cases, the stents were
widely patent on angiography.
● Assisted patency was determined by follow-up of pa-
tients who underwent repeat endovascular therapy
with a failure of primary patency. Patients whose recur-
rences were treated with an open bypass were consid-
ered failures of primary patency and were censored in
the assisted patency calculations.
● Radiologic recurrence was defined as stenosis 70%
on follow-up imaging including duplex scan, CTA,
and/or traditional mesenteric angiography, regardless
of symptoms. Imaging was available in 37 patients
(75.5%). Percent stenosis was calculated based upon
angiograms performed at the time of the procedure.
Duplex scan criteria for 70% stenosis were 275 cm/
second for the superior mesenteric artery/inferior
mesenteric artery (SMA/IMA) and 200 cm/second
for the celiac artery.
● Symptomatic recurrence was defined as the return of
original symptoms or new complaints suggestive of
CMI. Patients with symptomatic recurrences under-
went either noninvasive diagnostic imaging or angiog-
raphy to determine if reintervention was indicated.
● Overall survival or death from any cause was deter-
mined by reviewing hospital records. This assessment
also included searching the online Medicare Social
Security Death Index and telephone contact with pri-
mary physicians when possible.
● CMI-related-survival reported deaths that were sec-
ondary to the initial PTA/stent or subsequent mesen-
teric ischemia and deaths due to complications from
future associated procedures.
Procedural/stent details. All mesenteric interven-
tions were performed by vascular surgeons in angiographic
suites or endovascular operating rooms with fixed imaging
systems. Interventions were performed under local anes-
thesia with conscious sedation via a brachial (n  42;
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selection was based on patient anatomy and surgeon pref-
erence. Periprocedural systemic heparin was used in all
cases. Stenting was the preferred endovascular technique.
Upon angiographic confirmation of hemodynamically
significant lesions, 5 to 6F catheter delivery systems were
advanced proximal to the level of the mesenteric vessels,
and lateral aortography was performed. Angiography did
not routinely include inspiratory and expiratory images as a
method to assess for median arcuate ligament syndrome.
Angled selective catheters were used to engage the vessel
orifice, and lesions were crossed with platinum-tipped or
hydrophilic wires. Translesional pressure gradient measure-
ments were performed when the severity of the stenosis was
in question. Noncompliant balloon angioplasty to nominal
pressure or until lesion waist disappearance was performed.
Appropriately sized (4-8 mm) balloon-expandable stents
(BES) were used to treat residual orificial lesions (20%).
Most lesions involved the orifice of the mesenteric vessel;
stents were positioned to protrude slightly into the aortic
lumen. Self-expanding stents (SES) were only used for
nonorificial lesions. PTA was the sole procedure in 7 pa-
tients when it was not technically possible to deploy a stent.
Distal embolic protection, atherectomy devices, and lasers
were not used during PTA/stent procedures in this cohort.
All patients received 300 mg of clopidogrel after the pro-
cedure followed by 75 mg/day for 6 to 12 weeks. Patients
also received 325 mg of aspirin on the day of the procedure
and daily thereafter. Patients on warfarin for other medical
conditions were loaded with clopidogrel and then dis-
charged on warfarin and aspirin.
Statistics. Actuarial patency, recurrence, and survival
analysis was performed using Kaplan-Meier life tables. Pre-
Table I. Demographic data
Risk factor
Value
(n  49 patients) %
Age (years) 69.7  2.1 —
Female 41 83.7
Any CMI symptom (total symptoms) 49 (107) 100.0
Postprandial pain 45 91.8
Weight loss 5 lbs 28 57.1
Food fear 11 22.4
Nausea 12 24.5
Diarrhea 11 22.4
Tobacco use 28 57.1
Hypertension 44 89.8
Cardiac or cerebrovascular disease 32 65.3
Renal disease (Cr 1.5 mg/dL) 12 24.5
Hyperlipidemia 36 73.5
Lower extremity peripheral vascular
disease 19 38.8
Diabetes mellitus 5 10.2
COPD 8 16.3
Prior colon or small bowel surgery 6 12.2
Hypercoagulable disorder 6 12.2
CMI,Chronic mesenteric ischemia; lbs, pounds;COPD, chronic obstructive
pulmonary disease.dictors of outcomes were determined using a Mantel-Coxlog-rank univariate analysis. A multivariate analysis was not
performed due to the relative lack of significant univariate
predictors and the small sample size associated with sub-
group analysis. A P value of  .05 was considered signifi-
cant.
RESULTS
Patient cohort. Forty-nine patients underwent PTA/
stent for symptomatic CMI. All patients presented with
more than one CMI-related symptom (2.18 symptom/
patient), most commonly postprandial pain, and 98.0% had
1 atherosclerotic risk factor. Demographic and clinical
data are summarized in Table I.
In total, 66 mesenteric arteries were treated. Initial
symptom relief was reported by 44 patients (89.8%), and 5
(10.2%) had no change. Vessel-specific treatment details
Table II. Initial endovascular interventions performed
for CMI
Variable Number ( % )
Patients 49
Diseased mesenteric arteries (70%
stenosis by angiography) 100 (37 occluded)
One-vessel disease* 10 patients
Two-vessel disease 27 patients
Three-vessel disease 12 patients
Diseased vessels per patient 2.04
Vessels treated 66 (14 occluded)
Vessels treated per patient 1.35
Procedures (in 66 vessels)
BES 58 (87.9)
SES 1 (2.0)
PTA only 7 (14.3)
Approach (in 49 patients)
Brachial (all) 42 (85.7)
Left brachial 37
Right brachial 5
Femoral 7 (14.3)
PTA/stent procedures:
Celiac only (% of patients) 14 (28.6)
SMA only 14 (28.6)
IMA only 4 (8.1)
Celiac and SMA 14 (28.6)
Celiac and IMA 2 (4.1)
SMA and IMA 1 (2.0)
Celiac, SMA, and IMA 0 (0)
Median stent diameter (mm)
IMA (range) 4.0 (3.5 mm-5.0 mm)
SMA and celiac (range) 6.0 (5.0 mm-8.0 mm)
Brachial sheath 5 mm 13 (31.0)
Brachial sheath 6 mm 29 (69.0)
Technical success (at least one vessel
treated) 49 (100)
Technical success—all attempted vessels
in a patient 44 (89.8)
Initial clinical symptom relief 44/49 (89.8)
CMI, Chronic mesenteric ischemia; BES, balloon-expandable stent; SES,
self-expanding stent; PTA, percutaneous transluminal angioplasty; SMA,
superior mesenteric artery; IMA, inferior mesenteric artery.
*Five cases involving the SMA; three additional cases in which the IMA was
not well studied.are summarized in Table II. Single-vessel PTA/stent was
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tions in 17 (34.7%) with combined celiac and SMA treat-
ment in 14/17. The remaining three dual-vessel interven-
tions involved the IMA. All patients had 1 mesenteric
vessel successfully treated, however, intraprocedural tech-
nical success was 87.8% because four mesenteric occlusions
(3 SMA; 1 IMA) could not be crossed, and 1 IMA could
not be stented. Of the 66 successfully treated arteries, 52
(78.8%) were stenotic, and 14 (21.2%) were occluded on
preintervention arteriography.
A BES was used to treat 58/66 mesenteric vessels
(87.9%). PTA alone was utilized seven times (SMA  4;
IMA 2; celiac 1) and an SES once. Indications for PTA
included technical limitations to stenting (n  2) and
complete technical success with PTA (n  5). A non-ostial
long-segment SMA occlusion was treated with an SES. Me-
dian stent size for the SMA and celiac was 6.0mm (range, 5-8
mm) and 4.0 mm (range, 3.5-5.0 mm) for the IMA.
In-hospital mortality was 2.0%. This one early death
was from a myocardial infarction following mesenteric
PTA/stent and an open peripheral vascular bypass on the
same admission. Seven additional late deaths during the
follow-up period yielded an actuarial survival of 81.1% 
6.1% at 48 months (Fig 1) with causes including malig-
nancy, stroke, ischemic cardiomyopathy with acute event,
congestive heart failure in two, and three unknown causes
identified by the Social Security database. Mean follow-up
was 37.4  2.98 months.
Major complications occurred in 8 patients (14.3%).
Additionally, there were 6 brachial artery injuries requiring
reparative operations (12.2%; n  3 thrombosis; n  3
pseudoaneurysm). Two procedural-related strokes were as-
sociated with the brachial approach and calcified aortic
arches. One patient developed a transient left hemiparesis
following right brachial access (severe left subclavian steno-
Fig 1. Kaplan-Meier actuarial survival to 48 months.sis), and the other developed intraprocedural aphasia after aleft brachial approach that rapidly resolved. Both patients
were therapeutically anticoagulated when symptoms oc-
curred. One patient underwent focal small bowel resection
for ischemia 5 days after PTA/stent. One case of acute renal
failure required temporary hemodialysis (Table III).
Median total length of stay (tLOS) was 4 days, and the
median postprocedure stay was 2 days. (Median tLOS for
OR at this institution was 12 days.)4 Patients weremanaged
post-PTA/stent on a general vascular surgery floor and did
not require intensive care unit monitoring.
Patency. Actuarial primary patency was 78.8% 6.3%,
75.4%  6.9%, and 63.9%  8.5% at 12, 24, and 36
months, respectively. Assisted patency was 95.2%  3.3%
(12 months; Fig 2). Univariate analysis of variables affect-
ing primary patency identified two-vessel treatment (P 
.0064) as well as peripheral vascular disease, weight loss,
and hypertension as significant factors contributing to pa-
Fig 2. Kaplan-Meier primary and assisted patency to 36 months.
Table III. Mortality and major morbidity (n  49)
Event (n) (%)
Early mortality (in-hospital) 1 2.0
Late mortality 7 14.3
Mesenteric ischemia related mortality 0 —
Major morbidity* 8 16.3
Bowel ischemia 1
Stroke (non-fatal) 2
Acute renal failure (HD) 1
CHF 1
GI bleed 1
Infection 2
Brachial artery repair (pseudoaneurysm/thrombosis) 6 12.2
HD, Hemodialysis; CHF, congestive heart failure; GI, gastrointestinal.
*Resulted in prolonged of hospitalization.tency (Table IV, online only).
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obtained following PTA/stent in 37 patients (75.5%) with
restenosis detected in 64.9% (n  24) at a mean follow-up
of 8.5  1.9 months (range, 0-35) from the initial proce-
dure. A duplex scan (n 19; 51.4%) was the most common
initial study followed by CTA (n 13; 35.0%), mesenteric
angiography (n 4), and magnetic resonance angiography
(MRA) (n 1; only indirectly able to assess stent patency).
Significant restenosis was identified by duplex scan (n 
17), angiography (n  3), and CTA (n  3). Eleven
patients with radiologic recurrence remained asymptomatic
and did not subsequently require a reintervention. Actuar-
ial freedom from radiologic restenosis in patients with
radiologic follow-up was 51.6% 8.5%, 37.6% 8.7%, and
27.9%  8.8% at 12, 24, and 36 months, respectively (Fig
3).
Duplex velocity. Follow-up duplex scan velocity data
following PTA/stent were available in 18 patients (32.1%).
These tests included evaluation of vessel origins where the
stents are generally placed. Of these, 9 patients ultimately
required a reintervention, and 9 did not. Eight of 9 rein-
tervention patients were symptomatic, whereas all observa-
tion patients remained symptom-free. Peak systolic velocity
(PSV) measured in the treated artery between these groups
was similar (420.1  26.0 cm/second reintervention vs
Fig 3. Kaplan-Meier freedom from symptom recurrence, free-
dom from radiologic restenosis, and freedom from reintervention
to 36 months.403.2  36.5 cm/second no reintervention; P  .7116).However, end diastolic velocity (EDV) was significantly
greater in the reintervention group (169.1  32.1 cm/
second vs 78.9  16.1 cm/second; P  .0231).
Symptomatic recurrence. Fourteen patients (28.6%)
developed recurrent CMI symptoms during the study pe-
riod, a mean of 15.3 3.4 months (range, 1-36) following
the initial procedure. Actuarial freedom from symptomatic
recurrence was 80.7% 6.2%, 74.0% 7.2%, and 60.9%
9.4% at 12, 24, and 36 months (Fig 3); 13 of these patients
underwent second interventions. One 81-year-old female
originally underwent celiac PTA for high-grade stenosis
and CMI symptoms without complete relief and developed
symptomatic recurrence at 36 months with worsening
postprandial abdominal pain but no weight loss. She had
CT evidence of restenosis of the celiac artery but patent
SMA and IMA and, thus, did not undergo reintervention.
Univariate analysis identified two-vessel treatment (P 
.0014), peripheral vascular disease, and hypertension as
being associated with freedom from symptom recurrence
and linked celiac-only treatment (P  .0407) with symp-
tom recurrence (Table V, online only).
SMA occlusions. Outcome analysis of patients with
SMA occlusions (treated vs untreated) was performed.
Nearly half of the 23 occluded SMAs in the cohort (n 11)
were treated with PTA/stent, and the remainder (n  12)
alternatively had the celiac artery treated. Only one symp-
tomatic recurrence led to reintervention in the SMA-
treated group vs four symptomatic recurrences and five
reinterventions in the SMA-untreated group (P  .1739).
Three-year actuarial patency was 90% for treated SMA
occlusions vs 40% for SMA-untreated occlusions (P 
.1583).
Reinterventions. Fourteen patients (28.6%) required
a total of 19 reinterventions. Median time to first reinter-
vention was 15.5 4.3 months (range, 1-59). Reinterven-
tion for anatomic failure without symptoms was performed
once for a patient who initially underwent celiac PTA/stent
for a 90% stenosis with known SMA occlusion and patent
IMA. On subsequent duplex scan imaging, the IMA had a
70% stenosis, and PTA of this artery was performed. Con-
versions to OR occurred in five cases on an average of 8
months after the initial endovascular procedure. A second
endovascular intervention preceded OR in 4 of the 5 pa-
tients. All but 1 patient are alive and symptom-free; the one
death occurred 17 months after OR and was unrelated to
mesenteric ischemia. A complete revascularization, both
SMA and celiac, was performed in all cases. (Table VI,
online only).
Kaplan-Meier freedom from reintervention was 77.9%
6.5%, 74.5%  7.1%, and 63.2%  8.5% at 12, 24, and 36
months, respectively. Univariate analysis of variables affect-
ing reintervention found two-vessel treatment (P .0060),
hypertension, and peripheral vascular disease to be protec-
tive (Table VII, online only).
DISCUSSION
The current study is one of the three largest series to date
of CMI treated with endovascular therapy and has a mean
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other two.15,24 Three-year actuarial patency was 63%, despite
30% of patients developing recurrent symptoms requiring
reintervention. However, assisted patency was high (95% at
12 months), and no surgical bypass options were obviated by
the initial endovascular therapy. A high rate of radiologic
stenosis was identified by surveillance duplex scan, yet symp-
tom recurrencewas infrequent in these cases.NoCMI-related
deaths or AMI occurred during follow-up.
Primary patency varies significantly among recently
published series (27% to 92%) depending on the definition
of patency and length of follow-up.4,15,18,20,23,24 No con-
sensus exists for reporting long-term durability after endo-
vascular therapy for CMI. Several series, including our early
experience, document patency based on follow-up imag-
ing.4,6,23 This may lead to selection bias toward failures, as
patients with recurrent symptoms are more likely to un-
dergo further evaluation. Patency has also been defined as
continued symptom relief,26 which is clinically relevant, yet
not as sensitive as radiologic interrogation of the vessels.
Finally, patency has been based on Society for Vascular
Surgery guidelines citing the revised Rutherford lower ex-
tremity reporting standards (1997).15,27 These guidelines
were meant for determining bypass graft patency and did
not address PTA/stent. This heterogeneity in reporting
patency makes comparison across studies difficult. In the
current study, primary patency was determined by clinical
symptoms and radiologic follow-up with actuarial 36-
month primary patency 63.9%  8.5%, which compares
favorably with other endovascular series.5,6,14,20,22,28
The best radiographic surveillance method remains un-
known. Abdominal duplex scan is noninvasive, and velocity
criteria for stenosis have been previously validated for the
diagnosis of mesenteric arterial stenosis.29 However, the
accuracy of a duplex scan as the sole predictor of in-stent
restenosis is controversial.30,31 Indeed, our freedom from
radiologic restenosis, determined primarily by duplex scan,
was much lower than the freedom from reintervention;
thus, a group of asymptomatic patients with increased
duplex scan velocities were observed. Follow-up duration
for these patients did not differ from the remainder of the
group and, to date, none in this small cohort of asymptom-
atic patients has undergone further therapy or developed
AMI. Armstrong30 reported that in patients with increased
duplex scan velocities after mesenteric stenting, those who
required reintervention had a much higher mean PSV than
thosewhodidnot (530 vs 368 cm/second), and theEDVwas
very high as well (168 cm/second).30 This elevation in EDV
was also seen in the current study in patients who ultimately
required reintervention when compared to those who re-
mained asymptomatic. There was a lack of correlation be-
tween angiography and duplex scan in these patients. Angio-
graphic stenosis ranged from 0% to 90% despite elevated
duplex scan velocities. Further validation of velocity criteria
used to predict mesenteric in-stent restenosis is needed.
The literature on surgical reconstruction has shown
improved long-term outcomes when complete revascular-
ization of the celiac and SMA is achieved.10,12,28,32,33 Thisincludes two-vessel and single-vessel reconstructions when
the other major mesenteric artery is widely patent, which is
rare in symptomatic patients. Mateo et al12 found that all
CMI-related deaths occurred in incomplete revasculariza-
tion cases, concluding that despite more complications,
complete revascularization is preferred for its proven dura-
bility. McAfee et al33 showed improved graft patency and
survival with complete reconstruction, and Foley et al28
found a higher incidence of symptoms and graft failure with
single-vessel therapy. There were five open conversions in
the current series, and all had complete revascularizations;
three had confirmed patent celiac stents and underwent
aorta-SMA bypass only, whereas two had two-vessel recon-
structions (Table VI, online only).
The data herein indicate that two-vessel PTA/stenting
improves results for CMI.More than one-third of interven-
tions were two-vessel, most treating the SMA and celiac
arteries. Symptomatic recurrences were lower, patency im-
proved, and reinterventions were fewer. In addition, there
was a large difference (P  NS due to lack of power) in
3-year freedom from symptom recurrence between patients
undergoing revascularization of their occluded SMA and
those that did not. A reasonable conclusion to be drawn
from these data is that in patients who did not have the
SMA treated, symptom recurrence may be more likely, and
an open revascularization may become necessary. Recently
published endo-CMI series have had limited evaluation of
two-vessel vs one-vessel revascularizations.15,25
In a recent series by Sarac et al,15 which primarily
compared short-term results of endovascular therapy of
mesenteric artery occlusions and stenoses, there was not
any difference in 1-year patency between single-vessel and
two-vessel PTA/stenting. This group did not, however,
discuss the status of untreated vessels in the single-stent
patients. Indeed, they recommended stenting all stenotic
vessels whenever possible. Lee et al25 used a one-vessel
treatment approach and reported 2-year freedom from
symptom recurrence of only 56%. In general, there has
been a reluctance to treat total SMA occlusions. These
lesions tend to be bulky and calcified. It is possible that
stents placed across occlusions may not be as durable as
treated stenoses. Although there may be anatomic limita-
tions in some cases, our data support treating both the SMA
and celiac vessels, when anatomically possible, and warrants
close surveillance when unable to treat both.
The brachial approach for therapeutic endovascular
procedures is believed to result in more access-site arterial
injuries than the femoral approach. High success rates have
been reported with the latter.20,24 Our brachial complica-
tion rate of 12.4% compares with the access-site complica-
tions of Sarac et al,15 (15.4%) who used brachial access 70%
of the time and found femoral access was a predictor of
decreased 1-year patency, likely related to early technical
failure. Other contemporary endovascular series do not
specifically report access site complication rates. Despite
this, we favor the brachial approach (80%), as it facilitates
SMA access (especially when occluded), and access-related
complications can be repaired simply with local anesthesia.
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graphic surveillance is an inherent limitation of retrospec-
tive studies including the current series. Specifically, the
true incidence of symptom recurrence and radiographic
restenosis cannot be assessed in patients lost to follow-up.
Alternatively, there is likely bias toward more frequent
surveillance of patients with recurrent or persistent symp-
toms vs those who are asymptomatic. There remains uncer-
tainty about the true significance of duplex scan-predicted
restenosis due to the paucity of correlative mesenteric an-
giograms. Finally, several patients were identified by the
Social Security death index without known cause such that
CMI or subsequent AMI may have resulted in their deaths.
CONCLUSIONS
Intermediate follow-up suggests that significant radio-
logic restenosis and symptom recurrence are common fol-
lowing the endovascular treatment of symptomatic CMI.
Indeed, nearly 30% of these patients required reinterven-
tions, one-third of which were conversions to open surgical
bypass. However, both endovascular and open reinterven-
tions were well-tolerated, producing early favorable out-
comes with high assisted patency. Similar to the surgical
paradigm of two-vessel revascularization, endovascular
treatment of multiple mesenteric arteries produced better
outcomes. These results indicate that success with a first-
line endovascular approach to CMI is possible with careful
follow-up and reintervention for symptom recurrence.
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Robert H. Geelkerken, MD, PhD, Jeroen J. Kolkman, MD, PhD, and Ad B, Huisman, MD, PhD, Enschede,
The Netherlands
The article byMichael Peck et al describes a large single-center
experience of splanchnic artery stenting and as such it is valuable
for all physicians taking care of patients who are presenting with
this pathology.
There are four relevant take-home messages from the present
report: (1) at least 10% of patients with chronic abdominal symp-
toms and splanchnic artery stenoses does not perceive initial ben-
efit from revascularization; (2) the 1- and 3-year primary patency
rates were 79% and 64%, respectively; (3) the 1- and 3-year
symptom-free recurrence rates were 81% and 61%, respectively;
and (4) due to the improved symptom-free recurrence rate of
two-vessel revascularization as opposed to one-vessel, two-vessel
should be pursued.
Although there is an important caveat that should be kept in
mind when interpreting the results of this series, the difference
between primary patency and symptom-free recurrence indicates
that some patients have had (recurrent) symptoms without (recur-
rent) stenosis. This underscores how difficult the diagnosis of
chronic splanchnic ischemia sometimes is and how essential it is for
a valid functional test for assessing splanchnic blood flow. Gastric
exercise tonometry, validated over the past decade,1 is such a test
and has the ability to differentiate between asymptomatic splanch-positive function test is a prerequisite to prove the causal relation-
ship between chronic abdominal symptoms and splanchnic artery
stenoses.
Apart from the obvious downsides of a retrospective series, the
validity of this study clearly suffers from lack of a uniform indica-
tion and follow-up protocol. As a consequence, it is not clear
whether all patients with recurrent symptoms were identified; at
least 25% of the patients could have developed asymptomatic
restenosis. The observation that only 27% of the patients with
appropriate radiologic follow-up were free of restenosis is a further
indication that many recurrent stenoses may have been missed.
Although we agree with the authors that an endovascular-first
approach to chronic splanchnic ischemia can be defended, we
submit that these conclusions must be interpreted with caution as
they are based on retrospective series without a complete and
validated diagnostic process and without complete and objective
follow-up. At this time, however, this is the best available evidence.
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treatment; ASA, aspirin.
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January 2010147.e1 Peck et alTable IV, online only. Univariate analysis of variables
affecting primary patency
Variable
36-month primary patency
Yes (%) No (%) P value
Age 70 65% 62% .2971
Male gender 90% 56% .1206
Weight loss 77% 44% .0282
Food fear 55% 67% .3871
Nausea 50% 69% .2278
Diabetes 80% 62% .8867
Renal disease 73% 61% .4325
PVD 87% 48% .0354
Non-PVD cardiovascular
disease 59% 78% .1821
Hyperlipidemia 60% 82% .4612
HTN 73% 17%  .0001
Smoking history 71% 55% .1884
Colon or SB surgery 80% 62% .5756
Hypercoagulable 67% 63% .4872
1 vessel involved 64% 63% .8733
Two-vessel treatment 94% 43% .0064
Stent 7 mm 66% 56% .6214
ASA 56% 80% .3267
Plavix 58% 75% .4812
Coumadin 80% 63% .9822
PVD, Peripheral vascular disease; HTN, hypertension; SB, small bowel;
ASA, aspirin.Table V, online only. Univariate analysis of variables
affecting symptom recurrence
Variable
36-month freedom from
symptom recurrence
Yes (%) No (%) P value
Age 70 53% 57% .9979
Male gender 79% 45% .2522
Weight loss 64% 38% .1924
Food fear 55% 55% .4609
Nausea 28% 62% .4172
Renal disease 73% 49% .5421
PVD 87% 27% .0235
Non-PVD cardiovascular disease 45% 78% .2292
Hyperlipidemia 48% 82% .3922
HTN 61% 25% .0038
Smoking history 64% 39% .2417
Colon or SB surgery 80% 51% .4839
Hypercoagulable 67% 53% .5039
1 vessel involved 66% 36% .6759
Celiac only tx 18% 77% .0407
Two-vessel treatment 94% 16% .0014
Stent 7 mm 55% 49% .3193
ASA 64% 35% .4836
Plavix 53% 58% .8500
Coumadin 89% 53% .5074
PVD, Peripheral vascular disease; HTN, hypertension; SB, small bowel; tx,
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Volume 51, Number 1 Peck et al 147.e2Table VI, online only. Details of open reinterventions
Age Gender
Initial % stenosis
Cel/SMA Initial treatment Failure
Time to
failure Reintervention(s) Result
19 F 90/100 6 mm BES Cel Sx & Rad 1 mo
9 mos
6 mm BES Cel
Prograde aorta SMA BPG
6 mm ePTFE
Sx Rel
Sx Rel/Alive
65 F 90/90 6 mm BES Cel/SMA Sx & Rad 6 mos
4 mos
6 mm PTA Cel/SMA
Prograde aorto SMA/Cel
BPG
12  6 mm ePTFE
Sx Rel
Sx Rel/Alive
65 F 90/100 6 mm PTA SMA Sx & Rad 4 mos
4 mos
3 mos
7 mm BES SMA
7 mm BES Cel
ABF to SMA BPG
6 mm ePTFE
Sx Rel
Sx Rel
Sx Rel/Alive
82 F 90/100 7 mm BES Cel Sx & Rad 2 mos
4 days
7 mm BES Cel Origin
Prograde aorta SMA BPG
6 mm ePTFE & Rt
Hemicolectomy
Sx Rel
Sx Rel/died @ 17 mos
47 F 100/90 7 mm BES SMA Sx & Rad 8 mos Prograde aorta SMA/Cel
BPG
14  7 mm ePTFE
Sx Rel/Alive
BES, Balloon expandable stent; PTA, percutaneous transluminal angioplasty; Cel, celiac artery; SMA, superior mesenteric artery; BPG, open surgical bypass
graft; Sx, symptom recurrence; Rad, radiologic recurrence; Sx Rel, symptom relief; ABF, aortobifemoral bypass graft; ePTFE, expanded polytetrafluoroeth-
ylene.Table VII, online only. Univariate analysis of variables
affecting procedural reintervention
Variable
36-Month freedom from
reintervention
Yes (%) No (%) P value
Age 70 61% 66% .6358
Male gender 77% 58% .3690
Weight loss 73% 49% .0996
Food fear 55% 66% .3663
Nausea 55% 66% .6081
Renal disease 73% 61% .4771
PVD 87% 47% .0379
Non-PVD cardiovascular disease 58% 77% .1946
Hyperlipidemia 59% 82% .4690
HTN 70% 22% .0041
Smoking history 67% 58% .4641
Colon or SB surgery 80% 61% .5919
Hypercoagulable 67% 62% .4709
1 Vessel involved 61% 69% .6097
SMA and celiac tx 91% 53% .0832
Celiac only tx 44% 76% .0562
2 Vessel treatment 94% 42% .0060
Stent 7 mm 68% 49% .2445
ASA 57% 70% .7077
Plavix 58% 72% .4658
Coumadin 88% 61% .4449PVD, Peripheral vascular disease; HTN, hypertension; SB, small bowel;
SMA, superior mesenteric artery; tx, treatment; ASA, aspirin.
